Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Research & Development (2024 - 2025)

Indivior Pharmaceuticals has reported Research & Development over the past 2 years, most recently at $21.0 million for Q4 2025.

  • Quarterly results put Research & Development at $21.0 million for Q4 2025, down 32.26% from a year ago — trailing twelve months through Dec 2025 was $97.0 million (down 9.35% YoY), and the annual figure for FY2025 was $97.0 million, down 9.35%.
  • Research & Development for Q4 2025 was $21.0 million at Indivior Pharmaceuticals, down from $33.0 million in the prior quarter.
  • Over the last five years, Research & Development for INDV hit a ceiling of $33.0 million in Q3 2025 and a floor of $21.0 million in Q2 2025.